The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).
 
Ming-Huang Chen
No Relationships to Disclose
 
Wen-Chi Chou
No Relationships to Disclose
 
Chin-Fu Hsiao
No Relationships to Disclose
 
Yi-Chang Liu
No Relationships to Disclose
 
Chiun Hsu
Honoraria - Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Serono; MSD Oncology; Roche/Genentech; TTY Biopharm
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical
 
Shan Yanshen
No Relationships to Disclose
 
Yi-Ping Hung
No Relationships to Disclose
 
Chia-Hsun Hsieh
No Relationships to Disclose
 
Chao-Hua Chiu
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Roche
 
Ta-Chih Liu
No Relationships to Disclose
 
Shih-Feng Cho
No Relationships to Disclose
 
Tsang-Wu Liu
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose